QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: GVP Module IX Signal Management in EudraVigilance and the EU Regulatory Network

Test your understanding of the concepts covered by GVP Module IX: Signal Management in EudraVigilance and the EU Regulatory Network.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which sequence best represents the conceptual EU regulatory-network signal-management pathway?

Assessment, detection, confirmation, implementation, validation, prioritisation Detection, validation, confirmation, prioritisation, assessment, recommendation or action, follow-up Confirmation, implementation, detection, assessment, prioritisation, reporting Prioritisation, detection, regulatory action, validation, confirmation, follow-up

Question 2 of 10 Which evidence may appropriately contribute to a PRAC scientific assessment?

Only spontaneous reports in EudraVigilance Only the MAH's internal safety database EudraVigilance reports together with clinical-trial, literature, epidemiological, mechanistic, MAH and previous regulatory evidence Only evidence that supports a causal association

Question 3 of 10 An apparent increase in reporting is observed after a change in case coding and a major increase in product exposure. What should the assessment team do first?

Conclude that the incidence of the adverse reaction has increased. Assess data quality, coding, duplicates, reporting behaviour and exposure before interpreting the pattern as a change in risk. Exclude all cases reported after the coding change without review. Request an immediate product-information restriction solely on the basis of the reporting increase.

Question 4 of 10 What is the appropriate interpretation of notification of a signal or emerging safety issue?

It is a formal declaration that causality has been established. It indicates that a concern warrants regulatory attention, while scientific uncertainty may remain. It means that no further internal MAH assessment is permitted. It automatically requires a permanent product withdrawal.

Question 5 of 10 Which principle most accurately summarises the role of EudraVigilance in signal management?

It is solely an archival database with no role in signal detection. It converts every observed reporting pattern directly into a regulatory signal. It provides a major shared source of suspected adverse-reaction information that supports detection and assessment but requires expert interpretation. It is used only by MAHs and not by the EU regulatory network.

Question 6 of 10 Why should significant signal assessments be traceable to PSUR activities?

PSURs replace all signal-management procedures. Signals and regulatory assessments can inform aggregate safety evaluation, while PSUR evidence can inform future signal assessment. Only signals with confirmed causality may be mentioned in PSURs. Traceability is relevant only for centrally authorised products.

Question 7 of 10 Why is work sharing used for nationally authorised active substances marketed in several Member States?

To transfer all pharmacovigilance accountability from Member States to one company. To ensure that every NCA performs identical independent analyses of the same active substance. To allocate defined monitoring or assessment activities efficiently while allowing other authorities to contribute and retain responsibilities. To restrict signal assessment to centrally authorised medicines.

Question 8 of 10 Following implementation of a new risk-minimisation measure, what is the most mature next step?

Close the safety issue permanently once the measure is approved. Assess whether the measure achieved its intended purpose using an appropriate effectiveness-monitoring approach where required. Assume effectiveness because the measure was recommended by PRAC. Stop routine pharmacovigilance for the affected risk.

Question 9 of 10 Which statement best reflects the operational significance of the recent legal change described in the article?

The previous MAH EudraVigilance signal-detection pilot continues unchanged until GVP Module IX is formally revised. The legal change applies only to centrally authorised products. MAHs should consult the amended legislation and current EMA implementation guidance because legal requirements may have changed before the GVP text is updated. The legal change eliminates the need for MAHs to document signal-management activities.

Question 10 of 10 What is the correct relationship between signal management and the RMP?

The RMP is separate from signal management and should only be updated at fixed intervals. A regulatory conclusion may affect the safety specification, pharmacovigilance activities and risk-minimisation measures, so its implications should be integrated into the RMP lifecycle. Only a product-information change can justify consideration of an RMP update. The regulator's assessment removes the MAH's responsibility to evaluate RMP implications.

QPPV.com

Knowledge Assessment: GVP Module IX Signal Management in EudraVigilance and the EU Regulatory Network

Cookie Settings